Atlas Trials

Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301

Clinical trial NCT05534919 · COMPLETED

Trial details

NCT number
NCT05534919
Sponsor
Everest Medicines (Singapore) Pte. Ltd.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Primary Immunoglobulin a Nephropathy (IgAN)
Start date
2022-12-09
Primary completion
2024-07-17
Enrollment
21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.